Celgene
Search results
May 30, 2024 · On May 30, 2024, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adult patients with relapsed or refractory mantle cell lymphoma (MCL)...
May 15, 2024 · On May 15, 2024, the Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory follicular...
2 days ago · The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
- 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States
- (206) 582-1600
May 31, 2024 · Juno Therapeutics CEO Hans Bishop gave an update on the biotech company in an exclusive CNBC PRO interview with CNBC’s Meg Tirrell from JPMorgan’s Annual Healthcare Conference in San Francisco.
May 15, 2024 · The FDA granted accelerated approval to lisocabtagene maraleucel (Breyanzi; Juno Therapeutics) to treat adults with relapsed/refractory follicular lymphoma who have already received at least two other therapies.
May 16, 2024 · The US Food and Drug Administration has granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics /Bristol Myers Squibb) for adults with relapsed or refractory...
People also ask
Where is Juno Therapeutics located?
Is Juno Therapeutics (Juno) a delisted company?
How much did Juno Therapeutics Inc (Juno) earn?
Which companies do Juno Therapeutics investors own?
May 29, 2024 · Patients with newly diagnosed multiple myeloma (NDMM) typically receive induction therapy consisting of at least a proteasome inhibitor (PI), an immunomodulatory imide drug (IMiD), and a ...
